Executive Director, Conferences | Market Research, Conference Programming, Speaker Relationships
Checkpoint inhibition plays a complementary role in TIL-based adoptive cell therapy. While TIL therapy harnesses the body's natural defenses, tumors can use checkpoints to evade immune attack. Checkpoint inhibitors block these brakes, allowing the expanded TILs to recognize and kill cancer cells more effectively. This combination approach holds promise for improving the effectiveness of TIL therapy. We are excited to invite Dr Inge M Svane, from the University of Copenhagen; Dr Balkese Alhamad from King Abdullah International Medical Research Center, and Dr John Bridgeman from InstilBio, to share their work and insights into the role of checkpoint inhibition in TIL-based adoptive cell therapy, and demonstrate the benefit of next-generation TILs in anti-tumour activity and combination therapies. Meet these speakers and more at CHI's 8th Annual Immuno-Oncology Summit Europe taking place 23-25 April in London, UK. https://lnkd.in/etsmWHCY #immunooncology #TIL #cancertreatment #cancerresearch #immunotherapies #celltherapy #CAR #TCR
